Business
European Patent Granted
European Patent Granted.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n RNS Number : 1256W Allergy Therapeutics PLC 23 July 2009 \n \n23 July 2009\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n\nEuropean Patent Granted For MPL-Based Sublingual Vaccines\n\nAllergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that the European Patent office has granted a broad technology patent relating to the Company's family of MPL®-based sublingual allergy vaccines. This patent (jointly held with Corixa Inc) covers the use of glycolipid adjuvant administered sublingually with one or more antigens for use in the treatment of allergy or other diseases (infections, cancer or autoimmunity). \n\nAllergy Therapeutics' new generation of allergy vaccines use MPL®, an innovative TLR4-agonist, as an adjuvant to boost and accelerate the immune response of an allergy vaccine. Allergy Therapeutics has already conducted and previously reported results of a double-blind, placebo controlled, dose ranging Phase IIa MPL-based oral allergy vaccine study. The study (Study 103) was conducted in 80 grass-sensitive human subjects and involved the addition of MPL to Allergy Therapeutics' ORALVAC® grass pollen vaccine. This was the first time that any adjuvant had ever been clinically tested in an oral allergy vaccine and was also the first ever examination of oral delivery of MPL in humans. The results demonstrated that the vaccine was well tolerated and that, following an eight week treatment period, clinical symptoms improved and were accompanied by a characteristic pattern of immune response. \n\nDatamonitor estimates that the prevalence of allergic rhinitis (\"AR\") varies from 9.2% (Germany) to 17.2% (France) and that in the five major European markets the diagnosed AR population over 20 years of age is 28.3 million. However, under-diagnosis is substantial, with an estimated 44% of the AR population not diagnosed1. The value of the immunotherapy market in Europe is estimated to be more than €550 million.\n\nThe development of a convenient, e...